Small Molecules
11 September 2013
Conatus Pharmaceuticals’ Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population11 September 2013
Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase 2 Results11 September 2013
Ventrus Biosciences Announces Positive Results From Clinical Dermal Safety and Pharmacokinetic Studies of Diltiazem (VEN 307)11 September 2013
Syndax’s Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer11 September 2013
FDA Advisory Committee recommends approval in US of umeclidinium/vilanterol for the treatment of COPD10 September 2013
Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma10 September 2013
Ironwood and AstraZeneca Initiate Linaclotide Phase III Trial in China for Adults with IBS-C10 September 2013
RELYPSA REPORTS POSITIVE TOP-LINE RESULTS for the FIRST PART of its TWO-PART PIVOTAL PHASE 3 TRIAL OF PATIROMER10 September 2013
Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen(R) in a Feasibility Study10 September 2013
Verastem Initiates COMMAND: A Registration-Directed Trial of Defactinib in Patients with Mesothelioma10 September 2013
Relmada Therapeutics Announces Positive Results of LevoCap ER Pivotal Pharmacokinetic Study10 September 2013
Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency10 September 2013
XenoPort Announces Preliminary Results of Phase 1 Studies Supporting Further Development of XP2382910 September 2013
Alcobra’s Pre-Clinical Fragile X Study for MG01CI Shows Significant Positive Results10 September 2013
Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals10 September 2013
Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib in Patients With Advanced Hepatocellular Carcinoma10 September 2013
Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia9 September 2013
Olodaterol Shows Sustained Improvements in Lung Function in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)9 September 2013
Novartis continues to build its COPD pipeline and presents new data on investigational once-daily QVA149 at ERS9 September 2013
Genkyotex Receives FDA IND Approval for Phase II Clinical Study with First in Class NOX Inhibitor GKT1378319 September 2013
Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment of PainNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports